Fig. 8: Mogat1 inhibition enhances Anti-PD-1 therapy response in breast cancer and melanoma.
From: Mogat1 drives metabolic adaptations to evade immune surveillance
a, b Schematic representation of the experimental design for evaluating the effects of Mogat1 knockdown and anti-PD-1 therapy in mouse models. a MMTV-PyMT tumor cells (shCTRL or shMogat1) were implanted into FVB mice. b B16/F10 melanoma cells (shCTRL or shMogat1) were implanted into C57BL/6 mice. Mice received intraperitoneal injections of either IgG control antibody or anti-PD-1 antibody at the indicated time points. Created in BioRender. https://BioRender.com/9gwjt01. Tumor growth curves of c FVB mice in MMTV-PyMT breast cancer model and d C57BL/6 mice in B16/F10 melanoma model (n = 7 per group). Arrows indicate anti-PD-1 injection days. Kaplan-Meier survival curves of (e) FVB mice in MMTV-PyMT breast cancer model and (f) C57BL/6 mice in B16/F10 melanoma model (n = 7 per group). Arrows indicate anti-PD-1 injection days. g Graphical summary of Mogat1 drives metabolic adaptations to evade immune surveillance. Created in BioRender. https://BioRender.com/fhksjom. Data are representative of two independent experiments. Error bars in (c, d) represent standard error of the mean (SEM). Statistical significance for tumor growth curves (c, d) was determined using two-way ANOVA. Survival curves (e, f) were analyzed using the log-rank test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, not significant. Figure (a, b, g) are created by BioRender. Source data are provided as a Source Data file.
